Galenica AG (CH:GALE)
:GALE
Want to see CH:GALE full AI Analyst Report?
Top Page
Galenica AG
(GALE)
Select Model
Select Model
Rating:61Neutral
Price Target:
CHF87.00
▼(-3.28% Downside)
Action:Downgraded
Date:03/12/26
The score is supported by generally solid fundamentals (steady profitability and good cash conversion) but held back by increased leverage and weak near-term technical momentum. Valuation is moderately unattractive at ~26.9x earnings despite a ~2.46% dividend yield.
Positive Factors
Cash generation
Consistent free-cash-flow (272M in 2025, ~91% of net income) indicates strong cash conversion. Durable cash generation supports reinvestment in logistics and retail, funds dividends and debt service, and reduces reliance on external financing over the medium term.
Negative Factors
Rising leverage
Leverage increased materially to a debt-to-equity of ~0.72 with total debt at 1.06B, up from ~0.16 in 2023. Higher debt reduces financial flexibility, raises interest and refinancing risk, and makes the firm more vulnerable to earnings or rate shocks over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Cash generation
Consistent free-cash-flow (272M in 2025, ~91% of net income) indicates strong cash conversion. Durable cash generation supports reinvestment in logistics and retail, funds dividends and debt service, and reduces reliance on external financing over the medium term.
Read all positive factors
Galenica AG (GALE) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF4.23B
Dividend Yield2.36%
Average Volume (3M)91.35K
Price to Earnings (P/E)23.1
Beta (1Y)0.35
Revenue Growth5.47%
EPS Growth-0.96%
CountryCH
Employees4,511
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)3.63
Shares Outstanding50,000,000
10 Day Avg. Volume70,861
30 Day Avg. Volume91,351
Financial Highlights & Ratios
PEG Ratio-24.67
Price to Book (P/B)3.29
Price to Sales (P/S)1.18
P/FCF Ratio17.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF85.00Price Target Upside-5.50% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)3.92
Revenue Forecast (FY)CHF4.37B
Galenica AG Business Overview & Revenue Model
Company Description
Galenica AG stands as a leading healthcare services company, serving both the Swiss market and international clients. Its operations are organized into two principal divisions: "Products & Care" and "Logistics & IT." The "Products & Care" division...
How the Company Makes Money
Galenica primarily makes money through two main areas: (1) pharmaceutical wholesale and logistics and (2) pharmacy retail and associated services. In wholesale/logistics, it generates revenue by purchasing medicines and healthcare products from ma...
Galenica AG Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
63
Positive
Cash Flow
70
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.14B | 3.92B | 3.75B | 4.01B | 3.83B |
| Gross Profit | 428.80M | 1.09B | 387.60M | 374.13M | 350.55M |
| EBITDA | 339.18M | 331.31M | 306.92M | 290.46M | 300.33M |
| Net Income | 181.10M | 182.95M | 173.60M | 165.13M | 167.68M |
Balance Sheet | |||||
| Total Assets | 3.34B | 3.07B | 2.99B | 2.66B | 2.62B |
| Cash, Cash Equivalents and Short-Term Investments | 115.51M | 129.68M | 116.16M | 93.93M | 164.98M |
| Total Debt | 1.06B | 775.60M | 236.04M | 686.49M | 672.65M |
| Total Liabilities | 1.86B | 1.52B | 1.52B | 1.41B | 1.38B |
| Stockholders Equity | 1.48B | 1.55B | 1.47B | 1.25B | 1.23B |
Cash Flow | |||||
| Free Cash Flow | 272.35M | 192.34M | 149.34M | 166.51M | 273.02M |
| Operating Cash Flow | 299.76M | 264.70M | 225.71M | 236.87M | 333.10M |
| Investing Cash Flow | -333.14M | -151.08M | -124.17M | -130.62M | -88.34M |
| Financing Cash Flow | 19.20M | -100.22M | -79.05M | -177.21M | -139.53M |
Galenica AG Technical Analysis
Neutral
89.95
Price Trends
84.79
Negative
89.15
Negative
88.17
Negative
Market Momentum
0.01
Negative
50.61
Neutral
73.12
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:GALE, the sentiment is Neutral. The current price of 89.95 is above the 20-day moving average (MA) of 83.57, above the 50-day MA of 84.79, and above the 200-day MA of 88.17, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 50.61 is Neutral, neither overbought nor oversold. The STOCH value of 73.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CH:GALE.
Galenica AG Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | CHF4.95B | 33.55 | 9.76% | 1.43% | 14.84% | 23.77% | |
77 Outperform | CHF4.76B | 17.30 | 27.15% | 0.67% | -2.39% | 154.37% | |
64 Neutral | CHF2.69B | 30.61 | 23.76% | 0.45% | 13.93% | 28.92% | |
62 Neutral | CHF3.31B | 18.78 | 15.79% | 0.51% | 2.57% | 4.31% | |
61 Neutral | CHF4.23B | 23.14 | ― | 2.36% | 5.47% | -0.96% | |
61 Neutral | CHF1.89B | -17.08 | 4.57% | 2.31% | -5.54% | -264.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
CH:GALE
Galenica AG
84.10
0.24
0.29%
CH:BANB
Bachem Holding AG
66.60
13.14
24.58%
CH:MOVE
Medacta Group SA
133.80
2.42
1.84%
CH:SFZN
Siegfried Holding AG
72.40
-20.62
-22.17%
CH:TECN
Tecan Group AG
149.20
-11.48
-7.14%
CH:YPSN
Ypsomed Holding AG
353.60
-48.27
-12.01%
Galenica AG Corporate Events
Galenica posts robust early-2026 sales and reaffirms guidance on diversified growth
May 28, 2026
Galenica AG reported a strong start to 2026, with group sales up 7.3% to CHF 1,409.7 million in the first four months despite a mild flu season that weighed on demand for cold and pain medicines. Growth was driven by the pharmacy omni-channel netw...
Swiss Healthcare Players Unite to Expand Nationwide E‑Prescription Platform
Apr 27, 2026
Switzerland’s healthcare sector is pushing ahead with nationwide digitalisation of prescriptions through the “E‑Rezept Schweiz” platform, backed by the doctors’ association FMH, the pharmacists’ association phar...
Galenica Shareholders Back Board, Lift Dividend and Approve Capital Band
Apr 21, 2026
Shareholders of Galenica AG approved all board proposals at the company’s ninth ordinary annual general meeting, with 75.2% of voting share capital represented and the entire board, including chairman Markus R. Neuhaus, confirmed for another...
Galenica’s Bichsel Unit to Shut Drug Production, Cut 152 Jobs by 2026
Mar 12, 2026
Galenica’s subsidiary Bichsel will shut down its loss-making pharmaceutical manufacturing operations by the end of 2026 after a consultation process confirmed that continued production is not economically viable, despite past investments and...
Galenica lifts earnings, boosts dividend and raises mid‑term profit targets
Mar 10, 2026
Galenica reported a strong 2025 performance, with net sales up 5.5% to CHF 4.14 billion and adjusted EBIT rising 11.3% to CHF 234.8 million, driven by all business areas and supported by improved margins and tighter working capital management. The...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.